Novartis licenses radiopharma asset from Chinese biotech for $50M upfront
Novartis licenses radiopharma asset from Chinese biotech for $50M upfront
Novartis licenses radiopharma asset from Chinese biotech for $50M upfront
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page